Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Researchers reported on a Phase I/II dose escalation study of VEGF-2 gene therapy in 30 patients with stable and refractory exertional angina
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury